CK Life Sciences International (Holdings), Inc. (LSI) AI Stock Analysis

1 Followers

CK Life Sciences International (Holdings), Inc.

(Frankfurt:LSI)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Diversified environmental and health business modelExposure to both environmental solutions and health-related products gives CK Life Sciences more than one avenue for revenue generation. This diversification can support resilience across customer markets and reduce reliance on a single product category over the next several quarters.

Negative Factors

Sharp margin compression and operating lossesThe steep fall in gross margin and shift into operating losses indicate that the company’s current revenue base is generating materially less economic value. Unless margins recover, persistent losses could constrain reinvestment, weaken returns, and reduce the durability of earnings.

CK Life Sciences International (Holdings), Inc. (LSI) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 5.19B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -81.3
Beta (1Y): 1.13
Revenue Growth: -6.59%
EPS Growth: 79.41%
Country: Germany
Employees: 1,920
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model

Company Description

CK Life Sciences International (Holdings), Inc. operates as an investment company, which engages in the business of research and development, manufacturing, commercialization, marketing and selling of products and assets in nutraceuticals, pharmaceut...

CK Life Sciences International (Holdings), Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:LSI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:2096	73Outperform	HKD 28.02B	15.19	16.54%	1.90%	27.24%	79.48%
HK:2696	65Neutral	HKD 27.20B	26.74	20.41%	―	32.63%	8.74%
HK:1177	61Neutral	HKD 98.56B	35.63	7.56%	2.15%	14.57%	-31.09%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:1877	41Neutral	HKD 31.66B	-73.54	-7.23%	―	35.82%	54.40%
HK:1672	41Neutral	HKD 5.02B	-6.98	-28.15%	―	-59.39%	-130.04%

* Healthcare Sector Average

Performance Comparison

DE:LSI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:LSI	CK Life Sciences International (Holdings), Inc.	0.06	-0.03	-36.17%
HK:1177	Sino Biopharmaceutical	5.57	-1.38	-19.84%
HK:1672	Ascletis Pharma, Inc.	4.84	-8.93	-64.85%
HK:1877	Shanghai Junshi Biosciences Co., Ltd. Class H	15.74	-9.00	-36.38%
HK:2096	Simcere Pharmaceutical Group Limited	10.89	-2.60	-19.29%
HK:2696	Shanghai Henlius Biotech, Inc. Class H	49.98	-15.27	-23.40%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

CK Life Sciences International (Holdings), Inc. AI Stock Analysis